The data being submitted is from participants from the Knight-ADRC MAP study.

Genotyping for 4495 participants were generated through 10 different genotyping arrays (Infinium CoreExome-24, Infinium Neuro Consortium Array, Infinium Global Screening Array-24, Infinium OmniExpress-24, Illumina Human660W-Quad, Human610-Quad, Illumina Omni1-Quad, Affy UK Biobank Axiom, Infinium OmniExpressExome-8, and Illumina Human1M-Duo). In particular, 1955 AD cases (57% Females, 56% APOE4+, average age 74), 839 ADRD participants (51% females, 34% APOE4+, average age 63), and 1699 cognitively healthy participants (60% Females, 31% APOE4+, average age 74) individuals are being submitted. Approximately 85% of the samples are self-defined as “White”, and 10% are self-defined as “African-American”.

Total number of samples: 4,496

Female 2,597 57.8 %
Male 1,886 41.9 %

Total number of samples: 4,496

American Indian/Alaska Native6
Asian11
Native Hawaiian or Other Pacific Islander1
Black or African American566
White3,861
NA51

Total number of samples: 4,496

Not Hispanic or Latino
2,574
57.3%
Hispanic or Latino
27
0.6%
Not Applicable/Not Available
1,895
42.1%

Total number of samples: 4,496

AD
Control1,78339.7%
Case1,95843.5%
Dementia Lewy Bodies (DLB)
Case591.3%
Fronto Temporal Dementia (FTD)
Case1302.9%
Parkinson disease (PD)
Case200.4%
PSP
Case180.4%
Other
Case10.0%
Other52711.7%

Total number of samples: 4,496

  • 2219 (0.4%)
  • 23366 (8.1%)
  • 24136 (3.0%)
  • 331,971 (43.8%)
  • 341,512 (33.6%)
  • 44281 (6.3%)
  • NA211 (4.7%)